AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19038400 — intervention group
Group type: EXPERIMENTAL
Intervention: Common associated symptoms in patients with acute KD
Number of subjects: 198
Study 19038879 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-row, 0.5-mm multidetector CT angiography
Number of subjects: 291
Study 19038879 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary angiography
Number of subjects: 291
Study 19038879 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-vessel analysis of 866 vessels using multidetector CT angiography
Number of subjects: 291
Study 19038879 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease severity assessed by CT and conventional angiography
Number of subjects: 291
Study 19040767 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored programmes based on participants' individual assessment of their most important daily activities, implemented over 12 weeks and 24 weeks.
Number of subjects: 55
Study 19040767 — intervention group
Group type: COMPARATOR
Intervention: Usual care and treatment provided to the control group.
Number of subjects: 55
Study 19046447 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified nitrogen washout/washin technique
Number of subjects: 30
Study 19046447 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium dilution technique
Number of subjects: 30
Study 19047220 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine
Number of subjects: 61004
Study 19047220 — intervention group
Group type: COMPARATOR
Intervention: Control group (diphtheria, tetanus, acellular pertussis vaccine and separate doses of hepatitis B and inactivated poliovirus vaccines)
Number of subjects: 61004
Study 19047237 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair of pectus excavatum
Number of subjects: 264
Study 19054318 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission levels of activated factor XII type A (XIIaA)
Number of subjects: 870
Study 19054318 — intervention group
Group type: EXPERIMENTAL
Intervention: XIIaA in the highest quartile
Number of subjects: 870
Study 19054318 — intervention group
Group type: EXPERIMENTAL
Intervention: XIIaA
Number of subjects: 870
Study 19054318 — intervention group
Group type: EXPERIMENTAL
Intervention: XIIaA in patients with admission TnT <= 0.05 ng mL(-1)
Number of subjects: 870
Study 19055202 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise habits (self-reported); evaluated using the Paffenbarger Physical Activity and Exercise Index.
Number of subjects: 258
Study 19055202 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma control (measured by the Asthma Control Questionnaire); severity measured by the Severity of Asthma Scale.
Number of subjects: 258
Study 19055202 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level and obesity status (independent variables in multivariate analysis).
Number of subjects: 258
Study 19055202 — intervention group
Group type: EXPERIMENTAL
Intervention: Meeting national exercise guidelines (20 to 30 minutes of exercise 3 to 5 days a week).
Number of subjects: 258
Study 19055202 — intervention group
Group type: COMPARATOR
Intervention: Comparison with the general population regarding routine exercise.
Number of subjects: 258
Study 19055703 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI group (patients undergoing MRI scan)
Number of subjects: 470
Study 19055703 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients not undergoing MRI scan)
Number of subjects: 470
Study 19055828 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fitness (measured as peak oxygen uptake during treadmill testing)
Number of subjects: 217
Study 19055828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fatness (measured as percentage of total body fat by dual-energy x-ray absorptiometry)
Number of subjects: 217
Study 19055828 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes
Number of subjects: 217
Study 19056591 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg/kg methylcobalamin (2 times/wk) and 400 microg folinic acid (2 times/d) for 3 mo
Number of subjects: 40
Study 19056591 — intervention group
Group type: COMPARATOR
Intervention: Control children (age-matched)
Number of subjects: 40
Study 19057412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for 12 weeks
Number of subjects: 168
Study 19058002 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone 200 mg b.i.d, co-amoxiclav 1 g b.i.d., colloidal bismuth subcitrate 240 mg b.i.d., and esomeprazole 40 mg b.i.d. for 14 days
Number of subjects: 52
Study 19058002 — intervention group
Group type: COMPARATOR
Intervention: Classical triple therapy (not specified in detail)
Number of subjects: 52
Study 19061695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CRT and ICD system
Number of subjects: 1024
Study 19061695 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiVol fluid monitoring diagnostic data
Number of subjects: 1024
Study 19064724 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD-based induction chemotherapy followed by nonmyeloablative total body irradiation and allografting from an HLA-identical sibling
Number of subjects: 100
Study 19067714 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB treatments (6 to 9 sessions, 2 to 3 times weekly)
Number of subjects: 17
Study 19067714 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated vitiliginous skin)
Number of subjects: 17
Study 19067714 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated normal skin)
Number of subjects: 17
Study 19067714 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB exposure (1 MED)
Number of subjects: 17
Study 19068114 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash containing chlorine dioxide (ClO(2))
Number of subjects: 15
Study 19068114 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash without chlorine dioxide
Number of subjects: 15
Study 19068141 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional educational program for hypertension management involving physicians, nurses, and pharmacists.
Number of subjects: 5000
Study 19068141 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (experienced the intervention for at least 9 months).
Number of subjects: 5000
Study 19068141 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (not experienced the intervention yet).
Number of subjects: 5000
Study 19070891 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (40-46 Gy in 20-25 daily fractions, treating five times a week)
Number of subjects: 905
Study 19070891 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 905
Study 19070891 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from ASTEC and EN.5 trials
Number of subjects: 905
Study 19074928 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 1767
Study 19075070 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin at 25 mg/m(2) once daily as a 1-hour infusion
Number of subjects: 18
Study 19076979 — intervention group
Group type: EXPERIMENTAL
Intervention: SR29142 at 0.15 mg/kg per day
Number of subjects: 50
Study 19076979 — intervention group
Group type: EXPERIMENTAL
Intervention: SR29142 at 0.20 mg/kg per day
Number of subjects: 50
Study 19077198 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and treatment of chlamydial infection via vaginal swabs tested by PCR, with treatment for those infected.
Number of subjects: 2500
Study 19077198 — intervention group
Group type: COMPARATOR
Intervention: Control group with vaginal swabs stored and analyzed after a year, without immediate treatment.
Number of subjects: 2500
Study 19084893 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of care plans discussion within the first 24 hours of hospitalization
Number of subjects: 17097
Study 19084893 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a code status discussion (CD)
Number of subjects: 17097
Study 19084893 — intervention group
Group type: EXPERIMENTAL
Intervention: Site of enrollment
Number of subjects: 17097
Study 19084893 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal notations describing prehospital care wishes
Number of subjects: 17097
Study 19084893 — intervention group
Group type: COMPARATOR
Intervention: Legal care planning documents (durable power of attorney)
Number of subjects: 17097
Study 19084895 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement in discharge planning
Number of subjects: 403
Study 19084895 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of community support services
Number of subjects: 403
Study 19087147 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment for degenerative cervical radiculopathy, specific modalities not detailed, duration not specified.
Number of subjects: 0
Study 19087147 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis confirmed by magnetic resonance imaging (MRI).
Number of subjects: 0
Study 19087147 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG) used to rule out other conditions.
Number of subjects: 0
Study 19087222 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP >300 pg/ml
Number of subjects: 146
Study 19087222 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer >2000 ng/ml
Number of subjects: 146
Study 19087222 — intervention group
Group type: EXPERIMENTAL
Intervention: H-FABP >6 ng/ml
Number of subjects: 146
Study 19087222 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI >0.09 ng/ml
Number of subjects: 146
Study 19087222 — intervention group
Group type: EXPERIMENTAL
Intervention: myoglobin >70 ng/ml
Number of subjects: 146
Study 19087222 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 146
Study 19089707 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of obesity
Number of subjects: 2709
Study 19089707 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of overweight
Number of subjects: 2709
Study 19089707 — intervention group
Group type: COMPARATOR
Intervention: Comparison with national norms
Number of subjects: 2709
Study 19092346 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with gemcitabine (1000 mg/m²) and cisplatin (50 mg/m²) for 4 bi-weekly cycles
Number of subjects: 28
Study 19094074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (ATG) 120 mg
Number of subjects: 26
Study 19096013 — intervention group
Group type: EXPERIMENTAL
Intervention: R406, an inhibitor of Syk function, starting at 75 mg and escalating to 175 mg twice daily
Number of subjects: 16
Study 19096013 — intervention group
Group type: EXPERIMENTAL
Intervention: R406, an inhibitor of Syk function
Number of subjects: 16
Study 19098313 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal electrical stimulation using epiretinal prostheses with two-dimensional electrode arrays.
Number of subjects: 0
Study 19098313 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical techniques measuring brightness of electrically generated percepts.
Number of subjects: 0
Study 19103636 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg infusion at baseline and day 15, with 100 mg methylprednisolone at each infusion)
Number of subjects: 8
Study 19104367 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal mesh repair (anterior repair with mesh)
Number of subjects: 261
Study 19104367 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal mesh repair (posterior repair with mesh)
Number of subjects: 261
Study 19104367 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal mesh repair (combined anterior and posterior mesh repair)
Number of subjects: 261
Study 19104367 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal mesh repair
Number of subjects: 261
Study 19104368 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal mesh surgery
Number of subjects: 105
Study 19104516 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill intervention
Number of subjects: 0
Study 19104516 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19106083 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy with ABCB1 TT genotype (two variant alleles at nucleotide 3435)
Number of subjects: 2208
Study 19106083 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy with CYP2C19 loss-of-function alleles (*2, *3, *4, or *5)
Number of subjects: 2208
Study 19106083 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy with CYP2C19 loss-of-function alleles among patients undergoing percutaneous coronary intervention
Number of subjects: 2208
Study 19106084 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel in healthy subjects (162 subjects)
Number of subjects: 1639
Study 19106084 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel in acute coronary syndromes (1477 subjects)
Number of subjects: 1639
Study 19106667 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use when shock was absent
Number of subjects: 2838
Study 19106667 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital tourniquets
Number of subjects: 2838
Study 19106667 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department (ED) tourniquets
Number of subjects: 2838
Study 19106667 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet used
Number of subjects: 2838
Study 19106667 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use
Number of subjects: 2838
Study 19109557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib (300-600 mg twice daily for 14 or 21 days) plus etoposide (100-200 mg daily on days 1-3 and 8-10)
Number of subjects: 84
Study 19109557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib (600 mg) plus etoposide (100 mg)
Number of subjects: 84
Study 19109557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib (400 mg) plus etoposide (200 mg)
Number of subjects: 84
Study 19112508 — intervention group
Group type: EXPERIMENTAL
Intervention: CagA seropositivity
Number of subjects: 526
Study 19112508 — intervention group
Group type: EXPERIMENTAL
Intervention: CagA+ strains
Number of subjects: 526
Study 19114617 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 4615
Study 19114617 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk individuals with NGT
Number of subjects: 4615
Study 19114617 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with impaired glucose regulation
Number of subjects: 4615
Study 19114680 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin at 50 mg/m(2) once daily for 2 to 21 days (mean, 9.3 days)
Number of subjects: 9
Study 19116237 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-apoA-I FCR in obese men
Number of subjects: 87
Study 19116237 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-apoA-I FCR in nonobese men
Number of subjects: 87
Study 19116237 — intervention group
Group type: EXPERIMENTAL
Intervention: VLDL-apoB PR and HOMA-IR score in obese men
Number of subjects: 87
Study 19116237 — intervention group
Group type: EXPERIMENTAL
Intervention: VLDL-apoB PR and adiponectin in nonobese men
Number of subjects: 87
Study 19116237 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-apoA-I FCR in both groups
Number of subjects: 87
Study 19117345 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib dose escalation to 600 mg or 800 mg daily
Number of subjects: 106
Study 19117345 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib dose escalation based on protocol criteria
Number of subjects: 106
Study 19117345 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib dose escalation based on ELN recommendations
Number of subjects: 106
Study 19117867 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization growth standard
Number of subjects: 73
Study 19117867 — intervention group
Group type: COMPARATOR
Intervention: Centers for Disease Control and Prevention growth curves
Number of subjects: 73
Study 19117867 — intervention group
Group type: COMPARATOR
Intervention: Centers for Disease Control and Prevention charts
Number of subjects: 73
Study 19117897 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal infection (culture-proven sepsis, meningitis, necrotizing enterocolitis)
Number of subjects: 944
Study 19117897 — intervention group
Group type: EXPERIMENTAL
Intervention: Count of 3 neonatal morbidities (bronchopulmonary dysplasia, brain injury, severe retinopathy)
Number of subjects: 944
Study 19117897 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningitis
Number of subjects: 944
Study 19117897 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection or necrotizing enterocolitis
Number of subjects: 944
Study 19117897 — intervention group
Group type: COMPARATOR
Intervention: No specific control group mentioned
Number of subjects: 944
Study 19118066 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 DNA vaccine (3 mg)
Number of subjects: 15
Study 19118066 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 DNA vaccine (0.5 mg and 1 mg)
Number of subjects: 15
Study 19118066 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 DNA vaccine
Number of subjects: 15
Study 19119321 — intervention group
Group type: COMPARATOR
Intervention: Single-dose nevirapine (SD-NVP)
Number of subjects: 79
Study 19119321 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-week extended-dose nevirapine (SWEN)
Number of subjects: 79
Study 19121244 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke telemedicine
Number of subjects: 0
Study 19121244 — intervention group
Group type: EXPERIMENTAL
Intervention: Hub-and-spoke telestroke network
Number of subjects: 0
Study 19121244 — intervention group
Group type: EXPERIMENTAL
Intervention: Telestroke network
Number of subjects: 0
Study 19121244 — intervention group
Group type: EXPERIMENTAL
Intervention: State-based telestroke network
Number of subjects: 0
Study 19121244 — intervention group
Group type: EXPERIMENTAL
Intervention: International telestroke networks
Number of subjects: 0
Study 19121244 — intervention group
Group type: EXPERIMENTAL
Intervention: Future advances in telestroke practice
Number of subjects: 0
Study 19125991 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin treatment
Number of subjects: 744
Study 19130989 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Moderate-Intensity Exercise (CME)
Number of subjects: 8
Study 19130989 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 8
Study 19130989 — intervention group
Group type: COMPARATOR
Intervention: Control (rest before HFM)
Number of subjects: 8
Study 19131464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle (ILS) intervention
Number of subjects: 3188
Study 19131464 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3188
Study 19131464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3188
Study 19131464 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of groups
Number of subjects: 3188
Study 19131464 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes development
Number of subjects: 3188
Study 19131498 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagify PSE
Number of subjects: 662
Study 19131498 — intervention group
Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 662
Study 19133895 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling sessions based on Motivational Interviewing plus individualized written feedback (intervention group, IG)
Number of subjects: 126
Study 19133895 — intervention group
Group type: COMPARATOR
Intervention: Booklet on health behaviour (control group, CG)
Number of subjects: 126
Study 19139884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (anti-CTLA-4 monoclonal antibody)
Number of subjects: 8
Study 19141127 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FMT
Number of subjects: 37
Study 19141127 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Number of subjects: 37
Study 19141127 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF expression
Number of subjects: 37
Study 19141127 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67 labeling index
Number of subjects: 37
Study 19141127 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvessel density (MVD)
Number of subjects: 37
Study 19141590 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly bisphosphonates
Number of subjects: 0
Study 19141862 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD(neg) group
Number of subjects: 280
Study 19141862 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD(pos) group
Number of subjects: 280
Study 19141862 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD analysis
Number of subjects: 280
Study 19141862 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD results at weeks 16 to 22
Number of subjects: 280
Study 19142112 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole combined with escitalopram (maximum dosages of 20 mg/d for escitalopram and 30 mg/d for aripiprazole)
Number of subjects: 16
Study 19142112 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole combined with escitalopram
Number of subjects: 16
Study 19143927 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal ultrasound (US)
Number of subjects: 855
Study 19143927 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal ultrasound (US)
Number of subjects: 855
Study 19143927 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of patients with distal DVT
Number of subjects: 855
Study 19144941 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (180 microg per week) and ribavirin (1000 or 1200 mg per day) for 48 weeks
Number of subjects: 569
Study 19144941 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and ribavirin treatment
Number of subjects: 569
Study 19144982 — intervention group
Group type: EXPERIMENTAL
Intervention: MLL-AF4
Number of subjects: 184
Study 19144982 — intervention group
Group type: EXPERIMENTAL
Intervention: MLL-ENL
Number of subjects: 184
Study 19144982 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare MLL fusion genes
Number of subjects: 184
Study 19144982 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristic features of MLL(+) patients
Number of subjects: 184
Study 19151191 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 12